Glutamine antagonism attenuates physical and cognitive deficits in a model of MS.
Kristen R HollingerMatthew D SmithLeslie A KirbyEva PrchalovaJesse AltRana RaisPeter A CalabresiBarbara S SlusherPublished in: Neurology(R) neuroimmunology & neuroinflammation (2019)
JHU-083, a well-tolerated, brain penetrable glutamine antagonist, is a promising novel treatment for both the physical and cognitive deficits of MS.